What the FDA labels say about taking them together
Rivaroxaban and sugammadex
Sugammadex's FDA label of March 13, 2026 names rivaroxaban in its warnings and precautions section; the rivaroxaban labels PlainMeds reads (2) do not name sugammadex. The sugammadex label: “… K antagonists, unfractionated heparin, low molecular weight heparinoids, rivaroxaban, and dabigatran up to ~25% and ~50% at C max levels of sugammadex corresponding to 4 mg/kg and 16 mg/kg doses, respectively.”
Check it at the source: the rivaroxaban FDA label on DailyMed (effective September 10, 2026, Janssen Pharmaceuticals, Inc.); the sugammadex FDA label on DailyMed (effective March 13, 2026, Merck Sharp & Dohme LLC).
What does the rivaroxaban label say about sugammadex?
Rivaroxaban's label (effective September 10, 2026) and its 1 other brand-application label do not name sugammadex in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Xarelto), Janssen Pharmaceuticals, Inc., effective September 10, 2026 (SPL set 10db92f9-2300-4a80-836b-673e1ae91610), via openFDA; the full label on DailyMed
What does the sugammadex label say about rivaroxaban?
Sugammadex label, warnings and precautionsIn vitro experiments demonstrated additional aPTT and PT(INR) prolongations for sugammadex in combination with vitamin K antagonists, unfractionated heparin, low molecular weight heparinoids, rivaroxaban, and dabigatran up to ~25% and ~50% at C max levels of sugammadex corresponding to 4 mg/kg and 16 mg/kg doses, respectively.
Source: FDA drug label (BRIDION), Merck Sharp & Dohme LLC, effective March 13, 2026 (SPL set 5171d883-fe8f-482c-97ab-40b00975b64a), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Rivaroxaban | Sugammadex | |
|---|---|---|
| Labeled for | Atrial fibrillation, Heart attack and coronary artery disease, Blood clots (DVT and PE), Stroke prevention | n/a |
| Boxed warning | Yes | No |
| Pharmacy cost (NADAC) | $0.650 per tablet 2.5 mg tablet | n/a |
| Shortage now | A presentation being discontinued | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once